Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

Ann Oncol. 2019 Aug 1;30(8):1401-1403. doi: 10.1093/annonc/mdz160.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antineoplastic Agents, Immunological / administration & dosage*
  • DNA Helicases / genetics*
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Intravenous
  • Loss of Function Mutation
  • Middle Aged
  • Nuclear Proteins / genetics*
  • Response Evaluation Criteria in Solid Tumors
  • Rhabdoid Tumor / diagnostic imaging
  • Rhabdoid Tumor / drug therapy*
  • Rhabdoid Tumor / genetics
  • Rhabdoid Tumor / immunology
  • Thoracic Neoplasms / diagnostic imaging
  • Thoracic Neoplasms / drug therapy*
  • Thoracic Neoplasms / genetics
  • Thoracic Neoplasms / immunology
  • Time Factors
  • Tomography, X-Ray Computed
  • Transcription Factors / genetics*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Nuclear Proteins
  • SMARCA2 protein, human
  • Transcription Factors
  • pembrolizumab
  • SMARCA4 protein, human
  • DNA Helicases